Bioxytran's ProLectin-M Advances to Phase 3, Regulatory Discussions Underway
BIXT sits 21% above its 52-week low of $0.034 on light trading volume (0.2× avg).
Summary
Bioxytran announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, and is advancing towards a pivotal Phase 3 registrational trial. The company has initiated regulatory discussions with the U.S. FDA and India's CDSCO to finalize the design of a 408-patient study. This news builds directly on the positive Phase 1b/2a clinical trial results for ProLectin-M announced on March 2, providing the critical next step in the drug's development pathway. For a clinical-stage biotech, moving a lead candidate into Phase 3 and engaging with regulators is a highly material positive development, significantly de-risking the drug's path to potential market approval. Traders will now focus on updates regarding the finalization of the Phase 3 trial design and its initiation.
At the time of this announcement, BIXT was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.03 to $0.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.